Zimbabwe has launched Lenacapavir, a long-acting injectable HIV prevention drug in Harare, offering hope for at-risk populations.

This groundbreaking long-acting injectable medication is designed to prevent HIV infection and marks a significant advancement in the country’s efforts to combat the epidemic.

Health authorities officially launched the rollout of Lenacapavir, which requires administration only twice a year. Clinical studies have shown that this drug can provide near-complete protection against HIV acquisition, giving renewed hope for populations at high risk.

In the densely populated Epworth suburb of Harare, health officials, community leaders, and international development partners gathered to celebrate the introduction of this innovative drug, which experts believe could transform HIV prevention by decreasing reliance on daily medication.

Precious Chiwaya, a resident of Epworth and one of the first recipients, expressed her relief after being introduced to Lenacapavir. She noted that her previous reliance on oral pre-exposure prophylaxis often left her without sufficient supplies.

"I used to take oral PrEP, but sometimes the clinic only had a month's supply, and sometimes none at all," she recounted. "That was too risky for me. Now I have protection for six months without worrying about running out."

Such experiences highlight significant challenges with daily prevention approaches, where missed doses, stigma, and supply interruptions have hindered effectiveness, despite the availability of these methods.

The Zimbabwe Ministry of Health and Child Care reports significant progress in providing access to HIV treatment, with more than 1.3 million people living with HIV and over 90 percent receiving antiretroviral therapy. However, new infections among adolescent girls and young women remain a persistent concern.

Health Minister Dr. Douglas Mombeshora emphasized that the introduction of long-acting prevention methods reflects lessons learned from decades of HIV programming. He pointed out that prevention strategies must fit seamlessly into individuals' lives to ensure usage.

Civil society organizations involved in the HIV response are optimistic about Lenacapavir's potential to significantly reduce infection rates by improving adherence to treatment protocols. Imelda Mahaka of the Pangea Zimbabwe AIDS Trust noted this advancement could transform prevention efforts.

"Individuals who struggle to adhere to daily methods such as oral PrEP will benefit greatly from only needing two injections a year. This could lead to a meaningful decrease in new infections," she stated.

Public health experts are hopeful that long-acting prevention tools will particularly benefit young people, mobile populations, and individuals facing stigma when accessing HIV services.